Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Renal Cell × Dietary Supplements × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 8 Head and Neck Neoplasms 4 Pancreatic Neoplasms 3 Malnutrition 3 Lung Neoplasms 3 Carcinoma, Hepatocellular 3 Breast Neoplasms 3 Stomach Neoplasms 2 Prostatic Neoplasms 2 Lymphoma 2 Locally Advanced Head and Neck Carcinoma 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Cachexia 2 Wilms Tumor 1 Surgery--Complications 1 Sarcoma 1 Prostatic Intraepithelial Neoplasia 1 Peripheral Nervous System Diseases 1 Peptic Ulcer 1 Neurotoxicity Syndromes 1 Neurofibromatosis 1 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Multiple Endocrine Neoplasia Type 1 1 Mucositis 1 Motor Activity 1 Malabsorption Syndromes 1 Lymphoma, Large B-Cell, Diffuse 1

Interventions

Nivolumab 130 Sunitinib 120 pembrolizumab 116 Sorafenib 75 Everolimus 67 cabozantinib 66 Bevacizumab 66 pazopanib 60 Ipilimumab 55 Axitinib 55 aldesleukin 48 Magnetic Resonance Spectroscopy 41 Cyclophosphamide 36 Interleukin-2 33 Radiosurgery 32 Interferon-alpha 32 lenvatinib 31 Specimen Handling 29 temsirolimus 27 atezolizumab 24 belzutifan 21 fludarabine phosphate 20 Gemcitabine 20 avelumab 18 Radiotherapy 18 Interferon alpha-2 17 Biopsy 16 fludarabine 15 durvalumab 15 Paclitaxel 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05119010 2024-12-05

KETOREIN

Gustave Roussy, Cancer Campus, Grand Paris

Phase NA Terminated

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡